Navigation Links
Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research
Date:9/4/2013

VALENCIA, Calif., Sept. 4, 2013 /PRNewswire/ -- Sanguine BioSciences, a biotechnology company enabling personalized medicine research, today announced that it has signed commercial agreements with, and received orders from, more than 200 biomedical researchers at academic, biotechnology and pharmaceutical companies, to enable more efficient personalized medicine research. Ongoing agreements are in place with a wide range of organizations, ranging from startups, such as Inhibrx, to contract research organizations, such as Applied Immunology, and major drug developers, such as Vertex Pharmaceuticals.

Sanguine directly engages patients diagnosed with severe and chronic diseases to collect and de-identify biospecimen, medical history and other data that can be used in biomarker research. Traditional methods are to obtain biospecimen through hospitals, but this process can result in months of delays as the focus for physicians and staff is on diagnosis and treatment, not facilitating research efforts. By engaging patients directly, Sanguine can meet the needs of researchers and offer timely turnaround of biospecimen and medical data with diverse ranges for age, race, disease state, gender and treatments underway. The patient engagement tactics used by the company have led to a 95 percent retention rate, which also allow for follow-up draws for longitudinal studies.

"In a very short amount of time, and with only recently hiring our first few sales executives, our company has established agreements with ten of the largest drug developers in the world and continues to see high demand for our offering," said Brian Neman, founder and chief executive officer of Sanguine. "Researchers have specific needs to complete studies in early discovery work, sometimes run with blood samples drawn the same day and other times requiring follow-up draws on exact time schedules, but traditional strategies to obtain
'/>"/>

SOURCE Sanguine BioSciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology
2. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research, Co-Invest in Sanguine BioSciences
3. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
4. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
5. Rancho BioSciences Launches Rancho tranSMART Hosted for Clinical and Genomic Data Storage and Analysis
6. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
8. MD Biosciences Offers IL-23-Induced Psoriasis-Like Preclinical Model for Skin Inflammation
9. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
10. Flagship Biosciences Expands Digital Pathology with Pharmaceutical Biostatistics Services
11. Neurocrine Biosciences Reports Second Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and ... 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for ... owners and USDA-GIPSA inspection agencies that have a need to ... place in a matter of minutes with nothing but our ... feed and grain before accepting it, but they no longer ...
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... China, FORT LAUDERDALE, Fla., Sept. 5 ... pioneer in laser,optical breast cancer imaging systems, has ... Tianjin Medical University,s Cancer Institute and,Hospital, the largest ... http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ) Research at the Cancer ...
... EDMONTON, Sept. 5 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: ... of three-year survival results,from a randomized Phase II ... lung cancer (NSCLC). The results suggest that Stimuvax,combined ... benefits to,patients with unresectable stage IIIB NSCLC who ...
... FRANCISCO, Calif., Sept. 5 Hyperion,Therapeutics, a biopharmaceutical ... and hepatology therapies for the,treatment of Urea Cycle ... $40 million Series B financing. Leading the round ... Partners and,NEA, all of Menlo Park, CA. WRF ...
Cached Biology Technology:Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System 2Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System 3Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 2Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 3Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 4Hyperion Therapeutics Secures $40 Million In Series B Round 2
(Date:8/28/2014)... than traditional cigarettes, but still release toxins into ... USC. , Scientists studying secondhand smoke from e-cigarettes ... harmful particles, with close-to-zero exposure to organic carcinogens. ... in second-hand e-cigarette smoke were found to be ... levels of polycyclic aromatic hydrocarbons cancer-causing organic ...
(Date:8/28/2014)... groups and clinicians is critical to the development ... of Georgia research. , A qualitative study of ... that role models for successful breastfeeding help positively ... "Mothers who received that support are more likely ... Alex Anderson, an associate professor in the College ...
(Date:8/28/2014)... complex systems. Their infrastructure equipment requires ancillary sub-systems ... to supply fuel, and ICT systems for control ... is interconnected with a wider network and they ... scientists has studied various aspects of inter-network dependencies, ... in EPJ B by Gaihua Fu from Newcastle ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2Breastfeeding study shows need for effective peer counseling programs 2Inter-dependent networks stress test 2
... by Dr. Ann F. Jacobson, associate professor in Kent ... may initially choose to postpone but ultimately undergo total ... patient education before and after the procedure. ... pre-and post operative experiences with total knee replacement surgery, ...
... release is available in Spanish . , A ... (USA) and Nakai (China), among others, have deciphered for the first ... to the cover of the last issue of the prestigious journal ... to the group of Molecular Genetics of the Department of ...
... fund four faculty research projects for spring 2008. ... a number of excellent proposals submitted in response ... for the program is administered by the OSU ... by royalties from OSU-licensed technologies. These funded projects ...
Cached Biology News:Research examines factors in delaying or declining total knee replacement surgery 2Scientists decipher fruit tree genome for the first time 2Scientists decipher fruit tree genome for the first time 3OSU technologies funded for development 2OSU technologies funded for development 3
... Maxi MB (for aqueous, other low volatility ... systems respond to specific applications of molecular ... concentration of heat-labile samples. The RC systems ... cold traps and a wide selection of ...
... Acid Resistant SpeedVac Model SPD131DDA , Our ... SPD131DDA is designed to handle the rigors and ... slim design, digital display, dual independent timers, an ... chamber and vapor pathway. , , Adjustable ...
...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
Biology Products: